Europe Women’s Health Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Women’s Health Diagnostics Market Size

• The Europe Women’s Health Diagnostics Market size was valued at USD 33.29 billion in 2025 and is expected to reach USD 52.66 billion by 2033, at a CAGR of 5.90% during the forecast period
• The market growth is largely fueled by the increasing prevalence of chronic and lifestyle-related diseases among women, rising awareness regarding early disease detection, and growing emphasis on preventive healthcare, leading to higher adoption of advanced diagnostic solutions across healthcare settings
• Furthermore, increasing demand for accurate, early-stage diagnostic tools for conditions such as breast cancer, cervical cancer, and reproductive health disorders, along with advancements in imaging and molecular diagnostics, is establishing women’s health diagnostics as a critical component of modern healthcare. These converging factors are accelerating the uptake of women’s health diagnostic solutions, thereby significantly boosting the market’s growth

Europe Women’s Health Diagnostics Market Analysis

• Women’s health diagnostics, including imaging, molecular diagnostics, and screening tests, are increasingly vital in modern healthcare due to their role in early detection and management of conditions such as breast cancer, cervical cancer, osteoporosis, and reproductive health disorders
• The escalating demand for women’s health diagnostics is primarily driven by rising awareness regarding preventive healthcare, increasing prevalence of chronic diseases among women, and growing government initiatives supporting early screening and diagnosis
• The U.K. dominated the Europe Women’s Health Diagnostics Market with the largest revenue share of approximately 34.6% in 2025, supported by well-established healthcare infrastructure, widespread screening programs, and strong adoption of advanced diagnostic technologies
• Germany is expected to be the fastest-growing region in the Europe Women’s Health Diagnostics Market during the forecast period, with a projected CAGR of 8.6%, driven by increasing healthcare investments, rising awareness, and expanding diagnostic capabilities
• The lab-based testing segment dominated the largest market revenue share of 36.9% in 2025, driven by its high accuracy and reliability in diagnosing complex conditions

Report Scope and Europe Women’s Health Diagnostics Market Segmentation

Europe Women’s Health Diagnostics Market Trends

“Rising Adoption of Advanced Diagnostic Technologies in Women’s Health”

• A significant and accelerating trend in the global Europe Women’s Health Diagnostics Market is the growing adoption of advanced diagnostic technologies, including molecular diagnostics, point-of-care testing, and digital health platforms, which are enhancing early detection and disease management
• For instance, in recent years, companies such as Roche and Hologic have expanded their molecular diagnostic portfolios for cervical cancer and HPV screening, enabling faster and more accurate detection, thereby improving patient outcomes and supporting large-scale screening programs globally
• The increasing integration of automation and digital diagnostic platforms is streamlining laboratory workflows, reducing turnaround times, and improving the efficiency of diagnostic processes across hospitals and diagnostic centers
• The demand for non-invasive and minimally invasive diagnostic solutions is rising, particularly for conditions such as breast cancer, osteoporosis, and reproductive health disorders, supporting patient comfort and compliance
• Growing awareness regarding early disease detection and preventive healthcare among women is further accelerating the adoption of routine screening and diagnostic services globally
• The expansion of telehealth and remote diagnostic services is enabling better access to women’s health diagnostics, particularly in underserved and rural regions, contributing to broader market penetration
• Increasing collaborations between diagnostic companies and healthcare providers are fostering innovation and facilitating the development of more targeted and personalized diagnostic solutions
• The use of biomarkers and genetic testing is gaining traction in women’s health, particularly in oncology and fertility diagnostics, enabling more precise and individualized treatment approaches
• Rising investments in research and development are leading to the introduction of novel diagnostic assays and platforms, enhancing the overall quality and accuracy of testing
• This shift toward technologically advanced, accessible, and patient-centric diagnostic solutions is significantly reshaping the global Europe Women’s Health Diagnostics Market landscape

Europe Women’s Health Diagnostics Market Dynamics

Driver

“Increasing Prevalence of Women-Specific Disorders and Growing Awareness”

• The rising prevalence of women-specific health conditions such as breast cancer, cervical cancer, polycystic ovary syndrome (PCOS), and osteoporosis is a major driver fueling the demand for advanced diagnostic solutions globally
• For instance, according to global health organizations, breast cancer remains one of the most commonly diagnosed cancers among women worldwide, prompting governments and healthcare providers to implement large-scale screening initiatives, thereby boosting the demand for diagnostic technologies
• Increasing awareness regarding the importance of early diagnosis and preventive healthcare is encouraging women to undergo regular health check-ups and screenings
• Government initiatives and public health campaigns aimed at promoting women’s health are significantly supporting the adoption of diagnostic services across both developed and developing regions
• The growing focus on maternal health and reproductive health is driving the demand for prenatal and fertility diagnostics, contributing to overall market growth
• Advancements in diagnostic technologies are improving the accuracy and reliability of tests, thereby increasing trust and adoption among healthcare professionals and patients
• The expansion of healthcare infrastructure, particularly in emerging economies, is improving access to diagnostic services and supporting market expansion
• Increasing healthcare expenditure and insurance coverage for diagnostic procedures are making women’s health diagnostics more accessible to a broader population
• The rising geriatric female population is contributing to higher demand for diagnostics related to age-associated conditions such as osteoporosis and cancer
• The growing emphasis on personalized medicine is further driving the need for precise diagnostic tools, thereby supporting the growth of the Europe Women’s Health Diagnostics Market

Restraint/Challenge

“High Cost of Advanced Diagnostics and Limited Access in Low-Resource Settings”

• The high cost associated with advanced diagnostic technologies and procedures remains a significant challenge, particularly in low- and middle-income countries, limiting widespread adoption
• For instance, advanced molecular and genetic diagnostic tests for conditions such as cancer or fertility assessment can be expensive, making them less accessible to patients without adequate insurance coverage or financial resources
• Limited healthcare infrastructure in certain regions restricts access to high-quality diagnostic services, especially in rural and remote areas
• A shortage of skilled healthcare professionals and trained laboratory personnel can hinder the effective implementation and utilization of advanced diagnostic technologies
• Variability in regulatory frameworks across different countries can delay the approval and commercialization of new diagnostic products
• Lack of awareness and cultural barriers in some regions may prevent women from seeking timely diagnostic testing, impacting early disease detection
• Data privacy concerns associated with digital health and diagnostic platforms can pose challenges to adoption, particularly in technologically evolving markets
• The need for continuous maintenance and calibration of advanced diagnostic equipment adds to the operational costs for healthcare facilities
• Reimbursement challenges and limited insurance coverage for certain diagnostic tests can discourage patients from opting for advanced screening procedures
• Addressing these challenges through cost-effective solutions, improved healthcare infrastructure, and increased awareness will be critical for ensuring sustained growth in the Europe Women’s Health Diagnostics Market

Europe Women’s Health Diagnostics Market Scope

The market is segmented on the basis of application, tests, and end-user.

• By Application

On the basis of application, the Europe Women’s Health Diagnostics Market is segmented into Breast Cancer Testing, Cervical Cancer Testing, Pregnancy and Fertility Testing, Ovarian Cancer Testing, Infectious Disease Testing, Ultrasound Tests, Sexually Transmitted Disease Testing, and Others. The breast cancer testing segment dominated the largest market revenue share of 31.6% in 2025, driven by the high global prevalence of breast cancer and increasing awareness regarding early diagnosis. Governments and healthcare organizations are actively promoting screening programs such as mammography and genetic testing, significantly boosting demand. The segment benefits from continuous advancements in diagnostic technologies, including imaging and biomarker-based tests, improving accuracy and early detection rates. Rising adoption of preventive healthcare practices among women further supports growth. Additionally, favorable reimbursement policies in developed regions enhance accessibility to testing services. The segment is also supported by increasing investments in oncology diagnostics. Growing geriatric female population, which is more susceptible to breast cancer, further drives demand. The availability of advanced diagnostic infrastructure in hospitals and imaging centers contributes significantly. Increasing collaborations between diagnostic companies and healthcare providers strengthen the segment. Rising awareness campaigns globally continue to fuel adoption. These factors collectively reinforce the segment’s dominant position.

The pregnancy and fertility testing segment is expected to witness the fastest CAGR of 8.7% from 2026 to 2033, driven by rising infertility rates and increasing demand for reproductive health monitoring. Changing lifestyles, delayed pregnancies, and growing awareness about fertility health are key growth drivers. The segment benefits from the increasing adoption of home-based testing kits, including ovulation prediction kits and fertility monitors. Technological advancements in non-invasive and rapid diagnostic solutions further enhance adoption. Additionally, the growing availability of digital health platforms for fertility tracking supports market expansion. Increasing investments in reproductive healthcare services also contribute significantly. The segment is further driven by rising awareness regarding prenatal care and early pregnancy detection. Expanding healthcare access in emerging economies boosts demand. Growing preference for personalized healthcare solutions enhances uptake. Continuous innovation in diagnostic technologies strengthens growth prospects. These factors collectively drive rapid expansion of the segment.

• By Tests

On the basis of tests, the Europe Women’s Health Diagnostics Market is segmented into Biopsies, Other Breast Cancer Tests, Pregnancy and Fertility Testing, Lab-based Testing, Pregnancy Testing and Ovulation Prediction Kits, Fertility Monitors, Prenatal Genetic Screening and Carrier Testing, CF Testing, Down’s Syndrome and Edwards’ Syndrome Testing, TORCH Testing, Other Prenatal Genetic Disease Tests, Infectious Disease Testing, MRSA Testing, UTI Testing, Hepatitis Testing. The lab-based testing segment dominated the largest market revenue share of 36.9% in 2025, driven by its high accuracy and reliability in diagnosing complex conditions. Laboratory tests are widely used for detecting hormonal imbalances, infections, and genetic disorders, making them essential in women’s healthcare. The segment benefits from advanced diagnostic infrastructure and skilled professionals. Increasing prevalence of chronic and infectious diseases further supports demand. Additionally, the integration of automation and AI in laboratories enhances efficiency and reduces turnaround time. The segment is also supported by strong reimbursement frameworks in developed regions. Growing demand for comprehensive diagnostic panels boosts adoption. Rising awareness about preventive healthcare further contributes to growth. Increasing number of diagnostic laboratories globally strengthens accessibility. Continuous innovation in molecular diagnostics enhances capabilities. These factors collectively maintain the segment’s dominance.

The pregnancy testing and ovulation prediction kits segment is anticipated to witness the fastest CAGR of 9.3% from 2026 to 2033, driven by increasing demand for home-based and point-of-care diagnostics. These kits offer convenience, privacy, and quick results, making them highly preferred among women. The segment benefits from rising awareness about reproductive health. Technological advancements in digital and connected devices enhance user experience. Increasing e-commerce penetration supports product availability. Additionally, growing adoption among working women contributes significantly. The segment is also supported by affordable pricing and ease of use. Expanding product portfolios by key players further boost growth. Rising trend of self-monitoring healthcare solutions enhances adoption. Continuous innovation in test sensitivity and accuracy strengthens demand. These factors collectively accelerate segment growth.

• By End-User

On the basis of end-user, the Europe Women’s Health Diagnostics Market is segmented into Diagnostic and Imaging Centers, Hospitals and Clinics, and Home Care. The hospitals and clinics segment dominated the largest market revenue share of 48.2% in 2025, driven by the availability of comprehensive diagnostic services and advanced healthcare infrastructure. Hospitals serve as primary centers for disease diagnosis and management, increasing patient inflow. The segment benefits from skilled healthcare professionals and access to advanced diagnostic technologies. Increasing number of hospital visits for routine checkups and specialized treatments further supports growth. Additionally, strong reimbursement policies enhance affordability. The segment is also supported by rising investments in healthcare infrastructure globally. Growing prevalence of chronic diseases among women drives demand for diagnostic services. Integration of advanced imaging technologies improves diagnostic accuracy. Increasing government initiatives to promote women’s health further contribute. Continuous expansion of hospital networks enhances accessibility. These factors collectively ensure segment dominance.

The home care segment is expected to witness the fastest CAGR of 9.8% from 2026 to 2033, driven by the growing preference for convenient and cost-effective healthcare solutions. Home-based diagnostics allow patients to monitor health conditions without visiting healthcare facilities. The segment benefits from increasing availability of easy-to-use diagnostic kits. Rising awareness about self-care and preventive health supports adoption. Additionally, technological advancements in portable diagnostic devices enhance usability. The segment is also supported by increasing elderly population requiring regular monitoring. Growing digital health ecosystem further boosts growth. Expansion of telehealth services complements home diagnostics. Increasing consumer preference for privacy and comfort drives demand. Continuous innovation in home testing solutions strengthens the segment. These factors collectively drive rapid expansion of the home care segment.

Europe Women’s Health Diagnostics Market Regional Analysis

• The Europe Women’s Health Diagnostics Market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing healthcare investments, strong government-led screening programs, and rising awareness regarding early disease detection among women
• The region benefits from well-established healthcare systems and widespread access to diagnostic services, supporting the adoption of advanced diagnostic technologies
• In addition, the growing focus on preventive healthcare and early intervention is contributing to market expansion across European countries

U.K. Europe Women’s Health Diagnostics Market Insight

The U.K. Europe Women’s Health Diagnostics Market dominated with the largest revenue share of approximately 34.6% in 2025, supported by well-established healthcare infrastructure, widespread national screening programs, and strong adoption of advanced diagnostic technologies. The market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing awareness regarding women’s health and early diagnosis of diseases such as breast and cervical cancer. Furthermore, government initiatives, along with the presence of advanced diagnostic laboratories and a strong focus on preventive healthcare, are contributing to sustained market growth in the U.K.

Germany Europe Women’s Health Diagnostics Market Insight

The Germany Europe Women’s Health Diagnostics Market is expected to be the fastest-growing region during the forecast period, with a projected CAGR of 8.6%, driven by increasing healthcare investments, rising awareness regarding women’s health, and expanding diagnostic capabilities. Germany’s strong healthcare infrastructure, coupled with high healthcare expenditure and focus on technological innovation, is supporting the adoption of advanced diagnostic solutions. In addition, the growing emphasis on early disease detection and improved clinical outcomes is further promoting market growth across the country.

Europe Women’s Health Diagnostics Market Share

The Women’s Health Diagnostics industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott (U.S.)
• Siemens Healthineers AG (Germany)
• Hologic, Inc. (U.S.)
• BD (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Laboratory Corporation of America Holdings (U.S.)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (U.S.)
• PerkinElmer, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• Sysmex Corporation (Japan)
• Agilent Technologies, Inc. (U.S.)
• Danaher Corporation (U.S.)
• Illumina, Inc. (U.S.)
• Myriad Genetics, Inc. (U.S.)
• Natera, Inc. (U.S.)
• Exact Sciences Corporation (U.S.)
• Genomic Health, Inc. (U.S.)
• Fujifilm Holdings Corporation (Japan)

Latest Developments in Europe Women’s Health Diagnostics Market

• In May 2021, Hologic, Inc. announced that the U.S. Food and Drug Administration approved its Aptima SARS-CoV-2/Flu assay, expanding its molecular diagnostics portfolio widely used in women’s health testing platforms and strengthening its position in high-throughput diagnostic solutions
• In September 2021, F. Hoffmann-La Roche Ltd received FDA approval for its cobas HPV test for use on self-collected samples in clinical settings, marking a significant advancement in cervical cancer screening accessibility and early detection for women
• In March 2022, Becton, Dickinson and Company (BD) launched the BD COR MX/PX System globally, an automated high-throughput molecular diagnostics platform supporting HPV testing and other women’s health diagnostics, improving laboratory efficiency and accuracy
• In July 2022, Qiagen N.V. announced the expansion of its NeuMoDx molecular diagnostic system menu, including assays relevant to women’s health such as HPV and sexually transmitted infection (STI) testing, enhancing rapid and automated diagnostic capabilities
• In May 2023, Hologic, Inc. received CE-IVD marking for its Genius Digital Diagnostics System with Cervical AI algorithm, integrating artificial intelligence into cervical cancer screening to improve detection accuracy and workflow efficiency in cytology labs
• In January 2024, Becton, Dickinson and Company (BD) announced the launch of its BD Onclarity HPV Assay on the BD COR System in additional global markets, enabling extended genotyping and improved cervical cancer risk stratification
• In June 2024, Siemens Healthineers expanded its women’s health diagnostics portfolio by enhancing Atellica IM immunoassay solutions for reproductive and hormonal testing, supporting better diagnosis of fertility and endocrine disorders in women
• In February 2025, Roche announced expanded availability of its cobas HPV self-collection solution in international markets, aimed at increasing screening participation rates and improving early detection of cervical cancer globally
• In April 2025, Quest Diagnostics introduced expanded at-home diagnostic testing services for women’s health, including hormone, fertility, and STI testing panels, reflecting a growing shift toward decentralized and patient-centric diagnostics
• In July 2025, industry reports highlighted rapid adoption of AI-enabled imaging, molecular diagnostics, and point-of-care testing technologies in women’s health, driving improvements in early disease detection, personalized treatment planning, and access to care worldwide

SKU-46135